Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Proquad Market Size Forecast: How Large Could The Market Become By 2030?
The expansion of routine childhood vaccination programs, the rise in public health awareness campaigns, the accessibility of combination vaccines, improvements in pediatric healthcare infrastructure, and government-funded immunization initiatives have all contributed to the growth observed during the historic period.
The forecast period’s expansion is driven by broader global vaccination coverage goals, higher funding for next-generation vaccine R&D, stronger emphasis on tracking immunization adherence, more public-private collaborations in vaccination initiatives, and enhanced logistics for vaccine distribution. Key trends shaping this period involve greater use of combination vaccines, intensified efforts to boost pediatric immunization rates, widened national immunization campaigns, increased attention to cold chain efficiency, and more robust vaccine safety and surveillance frameworks.
Download A Free Sample Report For Comprehensive Market Insights:
Proquad Market Growth Factors Supporting Long-Term Expansion
The growing number of measles and chickenpox cases is expected to drive the expansion of the proquad market in the coming years. Measles is a highly contagious viral illness characterized by fever, coughing, and a red rash, which can be prevented through vaccination, whereas chickenpox is an infectious disease caused by the Varicella-zoster virus, presenting as an itchy, blister-like rash and also preventable with a vaccine. The increase in measles and chickenpox cases stems from declining vaccination rates, vaccine misinformation, heightened global travel, and outbreaks among unvaccinated groups, contributing to the resurgence of these preventable infections. Proquad is a combined vaccine targeting measles, mumps, rubella, and varicella (chickenpox) that provides immunity through a single shot, lowering infection risk, controlling disease spread, and offering broad protection to prevent complications from measles and chickenpox. For example, in May 2024, the World Health Organization, a Switzerland-based nonprofit, reported 56,634 measles cases and four deaths across 45 of 53 countries in the WHO European Region during the first quarter of 2024, compared to 61,070 cases and 13 deaths from 41 countries in all of 2023. Thus, the rising incidence of measles and chickenpox is fueling growth in the proquad market.
Proquad Market Driver: Increasing Healthcare Expenditures Driving Market Growth Due To Rising Demand For Advanced Medical Services And Innovative Treatments
Higher healthcare spending is expected to boost the proquad market’s expansion. Healthcare expenditures represent the total funds allocated to health-related services, products, and activities over a given timeframe, measured at the individual, community, national, or global level. These rising costs are fueled by factors such as the growing prevalence of chronic diseases, an aging population, progress in medical technology, and a greater need for sophisticated treatments and healthcare services. Healthcare expenditures support proquad by financing immunization initiatives, improving access, fostering public education, and building the infrastructure and insurance systems necessary for its widespread use and effectiveness. In May 2023, the Office for National Statistics, a UK government agency, noted that healthcare spending in the UK reached approximately $362 billion (£292 billion) in 2023, representing a nominal 5.6% rise, while long-term health and social care spending increased by 2.8% in real terms in 2022. Consequently, rising healthcare expenditure is propelling the proquad market forward.
Proquad Market Segment Analysis And Revenue Opportunities
The proquad market covered in this report is segmented –
1) By Indication: Measles, Mumps, Rubella, Varicella
2) By Patient Type: Pediatric Patient, Adult Patient
3) By End User: Healthcare Providers, Pharmacies, Public Health Organization
Proquad Market Industry Trends Shaping Future Revenue Growth
Companies within the proquad market are prioritizing the expansion of administration methods, specifically intramuscular (IM) delivery, to improve both convenience and consistency in vaccination processes. Intramuscular administration involves injecting a vaccine or medication directly into muscle tissue, which facilitates quicker absorption into the bloodstream. For example, in March 2023, Merck & Co. Inc., a pharmaceutical company headquartered in the United States, obtained approval from the U.S. Food and Drug Administration (FDA) to include an intramuscular administration option in the U.S. Product Insert (USPI) for its MMRV vaccine family, which encompasses ProQuad. This approval allows the MMRV family to align with other widely recommended vaccines that are given intramuscularly. Healthcare providers in the U.S. now have the flexibility to administer all routinely suggested injectable pediatric vaccines listed in the CDC immunization schedule using the same IM route. In the U.S., M-M-R II, VARIVAX, and ProQuad stand as the only measles, mumps, rubella, and varicella vaccines cleared for intramuscular administration. Furthermore, the MMRV vaccine family holds licensure for IM use across the European Union as well.
Proquad Market Leading Players Shaping Industry Direction
Major companies operating in the proquad market are Merck and Co. Inc.
Access The Complete Proquad Market Report:
Proquad Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the proquad market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the proquad market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model